Quality assurance in a large clinical trials consortium: the experience of the Tuberculosis Trials Consortium.
Quality assurance (QA) is essential for data accuracy and proper evaluation of study objectives in clinical trials. The Tuberculosis Trials Consortium (TBTC)-a collaboration of 28 clinical sites and the Centers for Disease Control and Prevention-has developed a comprehensive QA program that provides quantitative assessments of performance based on clearly defined standards that are communicated to data collectors through a feedback process. The Implementation and Quality Committee of the TBTC developed a Site Evaluation Report (SER) that assesses performance measures (PMs) critical to the accomplishment of study objectives. PMs are defined, quantified, and evaluated, and goals and minimum acceptable scores are specified. Sites not meeting a PM minimum must provide an explanation and develop a plan to meet the goal. Site-specific and system-wide problems can be readily identified through this process. The SER is used prospectively for all TBTC treatment trials, and a Web site has been developed to maximize the availability and usefulness of performance data. The TBTC's comprehensive QA program is an example of a successful method for ensuring high quality, evaluable data.
Sandman
Laurie
L
Bellevue Hospital, New York University School of Medicine, New York, NY, USA.
Mosher
Ann
A
Khan
Awal
A
Tapy
Jan
J
Condos
Rany
R
Ferrell
Scott
S
Vernon
Andrew
A
D000995:Antitubercular Agents / Q000008:administration & dosage*; D019992:Databases as Topic; D004311:Double-Blind Method; D006801:Humans; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D016032:Randomized Controlled Trials as Topic; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents